194 related articles for article (PubMed ID: 38025700)
1. In-silico study of antisense oligonucleotide antibiotics.
Chen ES; Ho ES
PeerJ; 2023; 11():e16343. PubMed ID: 38025700
[TBL] [Abstract][Full Text] [Related]
2. Identifying Antisense Oligonucleotides to Disrupt Small RNA Regulated Antibiotic Resistance via a Cell-Free Transcription-Translation Platform.
Tsai MJ; Zambrano RAI; Susas JL; Silva L; Takahashi MK
ACS Synth Biol; 2023 Aug; 12(8):2245-2251. PubMed ID: 37540186
[TBL] [Abstract][Full Text] [Related]
3. Coordination-Driven Self-Assembly of Metal Ion-Antisense Oligonucleotide Nanohybrids for Chronic Bacterial Infection Therapy.
Li A; Zhang Y; Wan L; Peng R; Zhang X; Guo Q; Xu S; Qiao D; Zheng P; Li N; Zhu W; Pan Q
ACS Appl Mater Interfaces; 2024 Jun; 16(22):28041-28055. PubMed ID: 38767982
[TBL] [Abstract][Full Text] [Related]
4. Disarmed anthrax toxin delivers antisense oligonucleotides and siRNA with high efficiency and low toxicity.
Dyer PDR; Shepherd TR; Gollings AS; Shorter SA; Gorringe-Pattrick MAM; Tang CK; Cattoz BN; Baillie L; Griffiths PC; Richardson SCW
J Control Release; 2015 Dec; 220(Pt A):316-328. PubMed ID: 26546271
[TBL] [Abstract][Full Text] [Related]
5. Targeting glmS Ribozyme with Chimeric Antisense Oligonucleotides for Antibacterial Drug Development.
Traykovska M; Popova KB; Penchovsky R
ACS Synth Biol; 2021 Nov; 10(11):3167-3176. PubMed ID: 34734706
[TBL] [Abstract][Full Text] [Related]
6. High-sensitivity quantification of antisense oligonucleotides for pharmacokinetic characterization.
Mahajan S; Zhao H; Kovacina K; Lachacz E; Hoxha S; Chan J; Liang M
Bioanalysis; 2022 May; 14(9):603-613. PubMed ID: 35578971
[TBL] [Abstract][Full Text] [Related]
7. Translation efficiency of mRNAs is increased by antisense oligonucleotides targeting upstream open reading frames.
Liang XH; Shen W; Sun H; Migawa MT; Vickers TA; Crooke ST
Nat Biotechnol; 2016 Aug; 34(8):875-80. PubMed ID: 27398791
[TBL] [Abstract][Full Text] [Related]
8. Advances in therapeutic bacterial antisense biotechnology.
Hegarty JP; Stewart DB
Appl Microbiol Biotechnol; 2018 Feb; 102(3):1055-1065. PubMed ID: 29209794
[TBL] [Abstract][Full Text] [Related]
9. Translation can affect the antisense activity of RNase H1-dependent oligonucleotides targeting mRNAs.
Liang XH; Nichols JG; Sun H; Crooke ST
Nucleic Acids Res; 2018 Jan; 46(1):293-313. PubMed ID: 29165591
[TBL] [Abstract][Full Text] [Related]
10. Estimated number of off-target candidate sites for antisense oligonucleotides in human mRNA sequences.
Yoshida T; Naito Y; Sasaki K; Uchida E; Sato Y; Naito M; Kawanishi T; Obika S; Inoue T
Genes Cells; 2018 Jun; 23(6):448-455. PubMed ID: 29667281
[TBL] [Abstract][Full Text] [Related]
11. General and Specific Cytotoxicity of Chimeric Antisense Oligonucleotides in Bacterial Cells and Human Cell Lines.
Popova KB; Penchovsky R
Antibiotics (Basel); 2024 Jan; 13(2):. PubMed ID: 38391508
[TBL] [Abstract][Full Text] [Related]
12. A novel integrated strategy (full length gene targeting) for mRNA accessible site tagging combined with microarray hybridization/RNase H cleavage to screen effective antisense oligonucleotides.
Sun Y; Duan M; Lin R; Wang D; Li C; Bo X; Wang S
Mol Vis; 2006 Nov; 12():1364-71. PubMed ID: 17149362
[TBL] [Abstract][Full Text] [Related]
13. Biomineralized Cascade Enzyme-Encapsulated ZIF-8 Nanoparticles Combined with Antisense Oligonucleotides for Drug-Resistant Bacteria Treatment.
Zhang Y; Lai L; Liu Y; Chen B; Yao J; Zheng P; Pan Q; Zhu W
ACS Appl Mater Interfaces; 2022 Feb; 14(5):6453-6464. PubMed ID: 35094518
[TBL] [Abstract][Full Text] [Related]
14. Reduction of Off-Target Effects of Gapmer Antisense Oligonucleotides by Oligonucleotide Extension.
Yasuhara H; Yoshida T; Sasaki K; Obika S; Inoue T
Mol Diagn Ther; 2022 Jan; 26(1):117-127. PubMed ID: 34994962
[TBL] [Abstract][Full Text] [Related]
15. Antisense oligonucleotide targeting CD39 improves anti-tumor T cell immunity.
Kashyap AS; Thelemann T; Klar R; Kallert SM; Festag J; Buchi M; Hinterwimmer L; Schell M; Michel S; Jaschinski F; Zippelius A
J Immunother Cancer; 2019 Mar; 7(1):67. PubMed ID: 30871609
[TBL] [Abstract][Full Text] [Related]
16. Engineering Antisense Oligonucleotides as Antibacterial Agents That Target FMN Riboswitches and Inhibit the Growth of
Traykovska M; Penchovsky R
ACS Synth Biol; 2022 May; 11(5):1845-1855. PubMed ID: 35440139
[TBL] [Abstract][Full Text] [Related]
17. Phosphorothioate Antisense Oligonucleotides Bind P-Body Proteins and Mediate P-Body Assembly.
Wang Y; Shen W; Liang XH; Crooke ST
Nucleic Acid Ther; 2019 Dec; 29(6):343-358. PubMed ID: 31429620
[TBL] [Abstract][Full Text] [Related]
18. Targeting FMN, TPP, SAM-I, and glmS Riboswitches with Chimeric Antisense Oligonucleotides for Completely Rational Antibacterial Drug Development.
Pavlova N; Traykovska M; Penchovsky R
Antibiotics (Basel); 2023 Nov; 12(11):. PubMed ID: 37998809
[TBL] [Abstract][Full Text] [Related]
19. Effects of combinations of gapmer antisense oligonucleotides on the target reduction.
Yanagidaira M; Yoshioka K; Nagata T; Nakao S; Miyata K; Yokota T
Mol Biol Rep; 2023 Apr; 50(4):3539-3546. PubMed ID: 36787053
[TBL] [Abstract][Full Text] [Related]
20. Investigation of the Activity of Antisense Oligonucleotides Targeting Multiple Genes by RNA-Sequencing.
Michel S; Klar R; Jaschinski F
Nucleic Acid Ther; 2021 Dec; 31(6):427-435. PubMed ID: 34251864
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
